New gel blocks blood flow to tumors and stops bleeding
NCT ID NCT06170619
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how well a gel-like material called Obsidio works to block blood vessels in people with hypervascular tumors or bleeding. 125 adults were treated, and researchers checked if the vessels were successfully blocked and if there were any serious side effects within 30 days. The goal was to confirm the device is safe and effective in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obsidio Conformable Embolic (a gel-like material injected into blood vessels to block blood flow)
What this could lead to
If successful, this registry confirms that Obsidio is a safe and effective option for blocking blood vessels to control bleeding or shrink tumors.
What could go wrong
This is a completed registry with 125 participants, so results are available but may not apply to all patients. Risks include unintended blockage of other vessels or injury to the target organ.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albany Medical Center
Albany, New York, 12208, United States
-
Barnes Jewish Hosital
St Louis, Missouri, 63110, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Christiana Hospital
Newark, Delaware, 19718, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Mercy Hospital
Coon Rapids, Minnesota, 55433, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
-
St. Joseph's Medical Center
Stockton, California, 95204, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University Hospital
Newark, New Jersey, 07103, United States
-
University of Chicago Hospital
Chicago, Illinois, 60637, United States
-
University of Kansas Hospital
Kansas City, Kansas, 66160, United States
-
University of North Carolina Hospital
Chapel Hill, North Carolina, 27599, United States
-
University of Texas Houston Health Science Center
Houston, Texas, 77030, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States